Real‐World Efficacy and Safety of Glofitamab‐Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B‐Cell Lymphomas
T-cell expansion (p = 0.02). Overall, glofitamab demonstrated durable efficacy and a manageable safety profile in R/R aggressive B-cell lymphoma, with treatment outcomes closely associated with T-cell functional status, supporting its potential as an effective bridging strategy before CAR-T therapy.
Authors
- Wanying Chen (ORCID: https://orcid.org/0000-0002-8650-4888)
- Kaiyu Sheng (ORCID: https://orcid.org/0009-0002-4769-038X)
- Q R Wang
- Xiangping Zong
- Yuxing Wang (ORCID: https://orcid.org/0000-0003-3079-5572)
- J Zhou
- Tao You
- Chenwen Wang
- Depei Wu
- Jia Chen
- Haiwen Huang (ORCID: https://orcid.org/0000-0002-1824-5247)
- Xiao Ma
Institutions
- Soochow University (CN)
- Second Affiliated Hospital of Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2026-05-10
- DOI
- https://doi.org/10.1002/ajh.70359
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00